|
1
|
Takano S, Yoshitomi H, Togawa A, Sogawa K,
Shida T, Kimura F, Shimizu H, Tomonaga T, Nomura F and Miyazaki M:
Apolipoprotein C-1 maintains cell survival by preventing from
apoptosis in pancreatic cancer cells. Oncogene. 27:2810–2822. 2008.
View Article : Google Scholar
|
|
2
|
Moulder R, Bhosale SD, Goodlett DR and
Lahesmaa R: Analysis of the plasma proteome using iTRAQ and
TMT-based Isobaric labeling. Mass Spectrom Rev. 37:583–606. 2018.
View Article : Google Scholar
|
|
3
|
Bhawal R, Oberg AL, Zhang S and Kohli M:
Challenges and opportunities in clinical applications of
blood-based proteomics in cancer. Cancers (Basel). 12:24282020.
View Article : Google Scholar
|
|
4
|
Sogawa K, Takano S, Iida F, Satoh M,
Tsuchida S, Kawashima Y, Yoshitomi H, Sanda A, Kodera Y, Takizawa
H, et al: Identification of a novel serum biomarker for pancreatic
cancer, C4b-binding protein α-chain (C4BPA) by quantitative
proteomic analysis using tandem mass tags. Br J Cancer.
115:949–956. 2016. View Article : Google Scholar
|
|
5
|
Mikami M, Tanabe K, Matsuo K, Miyazaki Y,
Miyazawa M, Hayashi M, Asai S, Ikeda M, Shida M, Hirasawa T, et al:
Fully-sialylated alpha-chain of complement 4-binding protein:
Diagnostic utility for ovarian clear cell carcinoma. Gynecol Oncol.
139:520–528. 2015. View Article : Google Scholar
|
|
6
|
Liu YS, Luo XY, Li QR, Li H, Li C, Ni H,
Li RX, Wang R, Hu HC, Pan YJ, et al: Shotgun and targeted
proteomics reveal that pre-surgery serum levels of LRG1, SAA, and
C4BP may refine prognosis of resected squamous cell lung cancer. J
Mol Cell Biol. 4:344–347. 2012. View Article : Google Scholar
|
|
7
|
Jia L, Zhang J, Ma T, Guo Y, Yu Y and Cui
J: The function of fucosylation in progression of lung cancer.
Front Oncol. 8:5652018. View Article : Google Scholar
|
|
8
|
Li D and Satomura S: Biomarkers for
hepatocellular carcinoma (HCC): An update. Adv Exp Med Biol.
867:179–193. 2015. View Article : Google Scholar
|
|
9
|
Jelski W and Mroczko B: Biochemical
diagnostics of pancreatic cancer-Present and future. Clin Chim
Acta. 498:47–51. 2019. View Article : Google Scholar
|
|
10
|
Tanabe K, Matsuo K, Miyazawa M, Hayashi M,
Ikeda M, Shida M, Hirasawa T, Sho R and Mikami M: UPLC-MS/MS based
diagnostics for epithelial ovarian cancer using fully sialylated
C4-binding protein. Biomed Chromatogr. 32:e41802018. View Article : Google Scholar
|
|
11
|
Umemura H, Nezu M, Kodera Y, Satoh M,
Kimura A, Tomonaga T and Nomura F: Effects of the time intervals
between venipuncture and serum preparation for serum peptidome
analysis by matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry. Clin Chim Acta. 406:179–180.
2009. View Article : Google Scholar
|
|
12
|
Narimatsu H, Iwasaki H, Nakayama F,
Ikehara Y, Kudo T, Nishihara S, Sugano K, Okura H, Fujita S and
Hirohashi S: Lewis and secretor gene dosages affect CA19-9 and
DU-PAN-2 serum levels in normal individuals and colorectal cancer
patients. Cancer Res. 58:512–518. 1998.
|
|
13
|
Kawa S, Oguchi H, Kobayashi T, Tokoo M,
Furuta S, Kanai M and Homma T: Elevated serum levels of Dupan-2 in
pancreatic cancer patients negative for Lewis blood group
phenotype. Br J Cancer. 64:899–902. 1991. View Article : Google Scholar
|
|
14
|
Stanczyk FZ and Clarke NJ: Advantages and
challenges of mass spectrometry assays for steroid hormones. J
Steroid Biochem Mol Biol. 121:491–495. 2010. View Article : Google Scholar
|
|
15
|
Farrell CJ, Martin S, McWhinney B, Straub
I, Williams P and Herrmann M: State-of-the-art vitamin D assays: A
comparison of automated immunoassays with liquid
chromatography-tandem mass spectrometry methods. Clin Chem.
58:531–542. 2012. View Article : Google Scholar
|
|
16
|
Soldin SJ, Soukhova N, Janicic N, Jonklaas
J and Soldin OP: The measurement of free thyroxine by isotope
dilution tandem mass spectrometry. Clin Chim Acta. 358:113–118.
2005. View Article : Google Scholar
|
|
17
|
Reis ES, Mastellos DC, Ricklin D,
Mantovani A and Lambris JD: Complement in cancer: Untangling an
intricate relationship. Nat Rev Immunol. 18:15–18. 2018. View Article : Google Scholar
|
|
18
|
Muinelo-Romay L, Vazquez-Martin C,
Villar-Portela S, Cuevas E, Gil-Martín E and Fernández-Briera A:
Expression and enzyme activity of alpha (1,6) fucosyltransferase in
human colorectal cancer. Int J Cancer. 123:641–646. 2008.
View Article : Google Scholar
|
|
19
|
Moriwaki K, Noda K, Furukawa Y, Ohshima K,
Uchiyama A, Nakagawa T, Taniguchi N, Daigo Y, Nakamura Y, Hayashi N
and Miyoshi E: Deficiency of GMDS leads to escape from NK
cell-mediated tumor surveillance through modulation of TRAIL
signaling. Gastroenterology. 137:188–198. 2009. View Article : Google Scholar
|
|
20
|
Lambert A, Schwarz L, Borbath I, Henry A,
Van Laethem JL, Malka D, Ducreux M and Conroy T: An update on
treatment options for pancreatic adenocarcinoma. Ther Adv Med
Oncol. 11:17588359198755682019. View Article : Google Scholar
|
|
21
|
Tran Cao HS, Zhang Q, Sada YH, Silberfein
EJ, Hsu C, Van Buren G II, Chai C, Katz MHG, Fisher WE and
Massarweh NN: Value of lymph node positivity in treatment planning
for early stage pancreatic cancer. Surgery. 162:557–567. 2017.
View Article : Google Scholar
|
|
22
|
Roche CJ, Hughes ML, Garvey CJ, Campbell
F, White DA, Jones L and Neoptolemos JP: CT and pathologic
assessment of prospective nodal staging in patients with ductal
adenocarcinoma of the head of the pancreas. AJR Am J Roentgenol.
180:475–480. 2003. View Article : Google Scholar
|
|
23
|
Tseng DS, van Santvoort HC, Fegrachi S,
Besselink MG, Zuithoff NP, Borel Rinkes IH, van Leeuwen MS and
Molenaar IQ: Diagnostic accuracy of CT in assessing extra-regional
lymphadenopathy in pancreatic and peri-ampullary cancer: A
systematic review and meta-analysis. Surg Oncol. 23:229–235. 2014.
View Article : Google Scholar
|
|
24
|
Nishiwada S, Sho M, Banwait JK, Yamamura
K, Akahori T, Nakamura K, Baba H and Goel A: A microRNA signature
identifies pancreatic ductal adenocarcinoma patients at risk for
lymph node metastases. Gastroenterology. 159:562–574. 2020.
View Article : Google Scholar
|
